Intrinsic value of RTI Surgical - RTIX

Previous Close

$4.75

  Intrinsic Value

$0.47

stock screener

  Rating & Target

str. sell

-90%

Previous close

$4.75

 
Intrinsic value

$0.47

 
Up/down potential

-90%

 
Rating

str. sell

We calculate the intrinsic value of RTIX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -3.19
  2.50
  2.75
  2.97
  3.18
  3.36
  3.52
  3.67
  3.80
  3.92
  4.03
  4.13
  4.22
  4.29
  4.36
  4.43
  4.49
  4.54
  4.58
  4.62
  4.66
  4.70
  4.73
  4.75
  4.78
  4.80
  4.82
  4.84
  4.85
  4.87
  4.88
Revenue, $m
  273
  287
  295
  304
  313
  324
  335
  348
  361
  375
  390
  406
  423
  441
  461
  481
  503
  526
  550
  575
  602
  630
  660
  691
  724
  759
  796
  834
  875
  917
  962
Variable operating expenses, $m
 
  304
  312
  321
  331
  342
  354
  366
  380
  395
  410
  420
  438
  457
  477
  498
  520
  544
  568
  595
  622
  652
  683
  715
  749
  785
  823
  863
  905
  949
  995
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  289
  304
  312
  321
  331
  342
  354
  366
  380
  395
  410
  420
  438
  457
  477
  498
  520
  544
  568
  595
  622
  652
  683
  715
  749
  785
  823
  863
  905
  949
  995
Operating income, $m
  -16
  -17
  -17
  -17
  -18
  -18
  -18
  -19
  -19
  -20
  -20
  -14
  -15
  -15
  -16
  -17
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -29
  -30
  -32
  -33
EBITDA, $m
  1
  6
  6
  6
  7
  7
  7
  7
  8
  8
  8
  9
  9
  9
  10
  10
  11
  11
  12
  12
  13
  13
  14
  15
  15
  16
  17
  18
  19
  19
  20
Interest expense (income), $m
  1
  3
  3
  3
  3
  4
  4
  4
  5
  5
  6
  6
  7
  7
  8
  8
  9
  10
  10
  11
  12
  13
  14
  15
  16
  17
  18
  19
  20
  21
  23
Earnings before tax, $m
  -17
  -19
  -20
  -20
  -21
  -22
  -22
  -23
  -24
  -25
  -26
  -20
  -21
  -22
  -23
  -25
  -26
  -28
  -29
  -31
  -33
  -34
  -36
  -38
  -40
  -43
  -45
  -48
  -50
  -53
  -56
Tax expense, $m
  -3
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -14
  -19
  -20
  -20
  -21
  -22
  -22
  -23
  -24
  -25
  -26
  -20
  -21
  -22
  -23
  -25
  -26
  -28
  -29
  -31
  -33
  -34
  -36
  -38
  -40
  -43
  -45
  -48
  -50
  -53
  -56

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  14
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  368
  355
  365
  376
  388
  401
  415
  430
  447
  464
  483
  503
  524
  546
  570
  595
  622
  650
  680
  712
  745
  780
  817
  855
  896
  939
  985
  1,032
  1,082
  1,135
  1,191
Adjusted assets (=assets-cash), $m
  354
  355
  365
  376
  388
  401
  415
  430
  447
  464
  483
  503
  524
  546
  570
  595
  622
  650
  680
  712
  745
  780
  817
  855
  896
  939
  985
  1,032
  1,082
  1,135
  1,191
Revenue / Adjusted assets
  0.771
  0.808
  0.808
  0.809
  0.807
  0.808
  0.807
  0.809
  0.808
  0.808
  0.807
  0.807
  0.807
  0.808
  0.809
  0.808
  0.809
  0.809
  0.809
  0.808
  0.808
  0.808
  0.808
  0.808
  0.808
  0.808
  0.808
  0.808
  0.809
  0.808
  0.808
Average production assets, $m
  109
  160
  164
  169
  174
  180
  186
  193
  201
  208
  217
  226
  235
  245
  256
  268
  280
  292
  306
  320
  335
  350
  367
  384
  403
  422
  442
  464
  486
  510
  535
Working capital, $m
  121
  96
  99
  102
  105
  108
  112
  116
  121
  126
  131
  136
  142
  148
  154
  161
  168
  176
  184
  193
  202
  211
  221
  232
  243
  254
  267
  279
  293
  307
  322
Total debt, $m
  83
  51
  56
  61
  67
  73
  80
  87
  95
  103
  112
  121
  131
  142
  153
  165
  178
  191
  206
  220
  236
  253
  270
  289
  308
  329
  350
  373
  397
  422
  448
Total liabilities, $m
  143
  169
  173
  179
  184
  190
  197
  204
  212
  220
  229
  239
  249
  260
  271
  283
  296
  309
  323
  338
  354
  370
  388
  406
  426
  446
  468
  490
  514
  539
  566
Total equity, $m
  225
  186
  192
  197
  204
  210
  218
  226
  234
  244
  253
  264
  275
  287
  299
  313
  327
  341
  357
  374
  391
  409
  429
  449
  471
  493
  517
  542
  568
  596
  625
Total liabilities and equity, $m
  368
  355
  365
  376
  388
  400
  415
  430
  446
  464
  482
  503
  524
  547
  570
  596
  623
  650
  680
  712
  745
  779
  817
  855
  897
  939
  985
  1,032
  1,082
  1,135
  1,191
Debt-to-equity ratio
  0.369
  0.270
  0.290
  0.310
  0.330
  0.350
  0.370
  0.380
  0.400
  0.420
  0.440
  0.460
  0.480
  0.490
  0.510
  0.530
  0.540
  0.560
  0.580
  0.590
  0.600
  0.620
  0.630
  0.640
  0.650
  0.670
  0.680
  0.690
  0.700
  0.710
  0.720
Adjusted equity ratio
  0.596
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525
  0.525

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -14
  -19
  -20
  -20
  -21
  -22
  -22
  -23
  -24
  -25
  -26
  -20
  -21
  -22
  -23
  -25
  -26
  -28
  -29
  -31
  -33
  -34
  -36
  -38
  -40
  -43
  -45
  -48
  -50
  -53
  -56
Depreciation, amort., depletion, $m
  17
  23
  23
  24
  24
  25
  26
  26
  27
  28
  29
  23
  24
  25
  26
  27
  28
  29
  31
  32
  33
  35
  37
  38
  40
  42
  44
  46
  49
  51
  53
Funds from operations, $m
  12
  4
  4
  3
  3
  3
  3
  3
  3
  3
  3
  3
  2
  2
  2
  2
  2
  2
  1
  1
  1
  1
  0
  0
  0
  -1
  -1
  -1
  -2
  -2
  -2
Change in working capital, $m
  -3
  2
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  6
  6
  6
  7
  7
  8
  8
  9
  9
  9
  10
  11
  11
  12
  12
  13
  14
  14
  15
Cash from operations, $m
  15
  1
  1
  0
  0
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -4
  -4
  -5
  -5
  -6
  -7
  -7
  -8
  -9
  -10
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -17
Maintenance CAPEX, $m
  0
  -16
  -16
  -16
  -17
  -17
  -18
  -19
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -31
  -32
  -33
  -35
  -37
  -38
  -40
  -42
  -44
  -46
  -49
  -51
New CAPEX, $m
  -18
  -4
  -4
  -5
  -5
  -6
  -6
  -7
  -7
  -8
  -8
  -9
  -10
  -10
  -11
  -11
  -12
  -13
  -13
  -14
  -15
  -16
  -17
  -17
  -18
  -19
  -20
  -21
  -23
  -24
  -25
Cash from investing activities, $m
  -18
  -20
  -20
  -21
  -22
  -23
  -24
  -26
  -26
  -28
  -29
  -31
  -33
  -34
  -36
  -37
  -39
  -41
  -42
  -45
  -47
  -49
  -52
  -54
  -56
  -59
  -62
  -65
  -69
  -73
  -76
Free cash flow, $m
  -3
  -18
  -19
  -21
  -22
  -24
  -25
  -27
  -28
  -30
  -32
  -33
  -35
  -37
  -40
  -42
  -44
  -47
  -49
  -52
  -55
  -58
  -61
  -65
  -68
  -72
  -76
  -80
  -84
  -89
  -93
Issuance/(repayment) of debt, $m
  4
  5
  5
  5
  6
  6
  7
  7
  8
  8
  9
  9
  10
  11
  11
  12
  13
  13
  14
  15
  16
  17
  18
  18
  19
  20
  22
  23
  24
  25
  26
Issuance/(repurchase) of shares, $m
  0
  24
  25
  26
  27
  28
  30
  31
  33
  34
  36
  30
  32
  34
  36
  38
  40
  42
  45
  47
  50
  53
  56
  59
  62
  65
  69
  73
  76
  81
  85
Cash from financing (excl. dividends), $m  
  4
  29
  30
  31
  33
  34
  37
  38
  41
  42
  45
  39
  42
  45
  47
  50
  53
  55
  59
  62
  66
  70
  74
  77
  81
  85
  91
  96
  100
  106
  111
Total cash flow (excl. dividends), $m
  1
  10
  10
  10
  11
  11
  11
  12
  12
  13
  13
  6
  7
  7
  8
  8
  9
  9
  10
  10
  11
  11
  12
  13
  13
  14
  15
  15
  16
  17
  18
Retained Cash Flow (-), $m
  13
  -24
  -25
  -26
  -27
  -28
  -30
  -31
  -33
  -34
  -36
  -30
  -32
  -34
  -36
  -38
  -40
  -42
  -45
  -47
  -50
  -53
  -56
  -59
  -62
  -65
  -69
  -73
  -76
  -81
  -85
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  7
  7
  7
  7
  8
  8
  8
  8
  9
  9
  9
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  16
  17
  17
  18
  19
  20
  21
  22
Cash available for distribution, $m
 
  -14
  -15
  -16
  -16
  -17
  -18
  -19
  -20
  -21
  -23
  -24
  -25
  -27
  -28
  -30
  -32
  -33
  -35
  -37
  -39
  -41
  -44
  -46
  -49
  -51
  -54
  -57
  -60
  -63
  -67
Discount rate, %
 
  5.60
  5.88
  6.17
  6.48
  6.81
  7.15
  7.50
  7.88
  8.27
  8.69
  9.12
  9.58
  10.06
  10.56
  11.09
  11.64
  12.22
  12.84
  13.48
  14.15
  14.86
  15.60
  16.38
  17.20
  18.06
  18.96
  19.91
  20.91
  21.95
  23.05
PV of cash for distribution, $m
 
  -13
  -13
  -13
  -13
  -12
  -12
  -12
  -11
  -11
  -10
  -9
  -8
  -8
  -7
  -6
  -5
  -5
  -4
  -3
  -3
  -2
  -2
  -1
  -1
  -1
  -1
  0
  0
  0
  0
Current shareholders' claim on cash, %
  100
  92.3
  85.1
  78.3
  71.9
  66.0
  60.6
  55.5
  50.8
  46.5
  42.5
  39.5
  36.6
  33.9
  31.4
  29.1
  26.9
  24.8
  22.9
  21.1
  19.4
  17.9
  16.5
  15.1
  13.9
  12.8
  11.7
  10.8
  9.9
  9.1
  8.3

RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company's business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world.

FINANCIAL RATIOS  of  RTI Surgical (RTIX)

Valuation Ratios
P/E Ratio -19.7
Price to Sales 1
Price to Book 1.2
Price to Tangible Book
Price to Cash Flow 18.4
Price to Free Cash Flow -91.9
Growth Rates
Sales Growth Rate -3.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate -33.8%
Financial Strength
Quick Ratio 2
Current Ratio 0
LT Debt to Equity 34.2%
Total Debt to Equity 36.9%
Interest Coverage -16
Management Effectiveness
Return On Assets -3.5%
Ret/ On Assets - 3 Yr. Avg. 0.6%
Return On Total Capital -4.5%
Ret/ On T. Cap. - 3 Yr. Avg. 0.5%
Return On Equity -6%
Return On Equity - 3 Yr. Avg. 0.6%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 48.4%
Gross Margin - 3 Yr. Avg. 50.8%
EBITDA Margin 0.4%
EBITDA Margin - 3 Yr. Avg. 7.6%
Operating Margin -5.9%
Oper. Margin - 3 Yr. Avg. 1.6%
Pre-Tax Margin -6.2%
Pre-Tax Margin - 3 Yr. Avg. 1.1%
Net Profit Margin -5.1%
Net Profit Margin - 3 Yr. Avg. 0.4%
Effective Tax Rate 17.6%
Eff/ Tax Rate - 3 Yr. Avg. 25.8%
Payout Ratio 0%

RTIX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the RTIX stock intrinsic value calculation we used $280 million for the last fiscal year's total revenue generated by RTI Surgical. The default revenue input number comes from 2016 income statement of RTI Surgical. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our RTIX stock valuation model: a) initial revenue growth rate of 2.5% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.6%, whose default value for RTIX is calculated based on our internal credit rating of RTI Surgical, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of RTI Surgical.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of RTIX stock the variable cost ratio is equal to 105.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for RTIX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for RTI Surgical.

Corporate tax rate of 27% is the nominal tax rate for RTI Surgical. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the RTIX stock is equal to 2.4%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for RTIX are equal to 55.6%.

Life of production assets of 10 years is the average useful life of capital assets used in RTI Surgical operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for RTIX is equal to 33.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $182 million for RTI Surgical - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 60 million for RTI Surgical is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of RTI Surgical at the current share price and the inputted number of shares is $0.3 billion.

RELATED COMPANIES Price Int.Val. Rating
OFIX Orthofix Inter 60.02 71.28  buy
ZBH Zimmer Biomet 111.66 61.79  sell
IART Integra LifeSc 62.95 29.67  sell
NUVA NuVasive 53.61 21.57  str.sell
SPNE SeaSpine Holdi 12.78 1.48  str.sell
VCEL Vericel 10.60 6.66  sell
SYK Stryker 174.30 73.42  str.sell

COMPANY NEWS

▶ Top Undervalued NasdaqCM Stocks This Month   [May-05-18 10:02AM  Simply Wall St.]
▶ RTI Surgical: 1Q Earnings Snapshot   [08:20AM  Associated Press]
▶ RTI Surgical reports 4Q loss   [05:59AM  Associated Press]
▶ Venture capital-backed Zyga Technology sold to Florida firm   [Jan-08-18 11:20AM  American City Business Journals]
▶ RTI Surgical Outlines 2018 Guidance and Long-Term Goals   [Jan-05-18 07:00AM  Business Wire]
▶ RTI Surgical Announces Acquisition of Zyga Technology, Inc.   [Jan-04-18 04:30PM  Business Wire]
▶ RTI Surgical meets 3Q profit forecasts   [Nov-02-17 08:58AM  Associated Press]
▶ Should You Be Holding RTI Surgical Inc (RTIX) Right Now?   [Oct-05-17 06:16PM  Simply Wall St.]
▶ RTI Surgical reports 2Q loss   [Aug-08-17 05:24PM  Associated Press]
▶ ETFs with exposure to RTI Surgical, Inc. : June 29, 2017   [Jun-29-17 03:17PM  Capital Cube]
▶ 5 Stocks to Gain on New Analyst Coverage   [Jun-15-17 08:24AM  Zacks]
▶ RTI Surgical® Partners in New Manufacturing USA Institute   [Jun-02-17 11:00AM  Business Wire]
▶ ETFs with exposure to RTI Surgical, Inc. : May 31, 2017   [May-31-17 12:45PM  Capital Cube]
▶ ETFs with exposure to RTI Surgical, Inc. : May 15, 2017   [May-15-17 04:32PM  Capital Cube]
▶ ETFs with exposure to RTI Surgical, Inc. : May 5, 2017   [May-05-17 04:31PM  Capital Cube]
▶ RTI Surgical reports 1Q loss   [Apr-27-17 09:34AM  Associated Press]
▶ ETFs with exposure to RTI Surgical, Inc. : April 17, 2017   [Apr-17-17 01:05PM  Capital Cube]
▶ ETFs with exposure to RTI Surgical, Inc. : April 5, 2017   [Apr-05-17 05:24PM  Capital Cube]
▶ RTI Surgical reports 4Q loss   [08:27AM  Associated Press]
▶ RTI Surgical Names Camille Farhat Chief Executive Officer   [Jan-26-17 08:30AM  Business Wire]
▶ RTI Surgical® Names Robert P. Jordheim Interim CEO   [Dec-14-16 08:02AM  Business Wire]
▶ Hedge Funds Are Dumping RTI Surgical Inc (RTIX)   [07:27AM  at Insider Monkey]
Financial statements of RTIX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.